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Systemic sclerosis (SSc) is an orphan con-
nective tissue disease characterised by skin
and multiorgan involvement. The following
original pathological processes distinguish
SSc from other connective tissue diseases:
(1) microvascular modifications, initially
functional and partly reversible, (2) perivas-
cular inflammation which appears to be
moderate and perhaps transitory, (3) auto-
immune activation, leading to the produc-
tion of specific and persistent autoantibodies
and (4) fibroblast activation, producing an
excess of extracellular matrix leading to
fibrosis.1 Therefore, SSc is a complex disease
with the implication of multiple players in its
pathogenesis.
SSc is a major medical challenge with high
mortality and morbidity. In a meta-analysis,
the pooled standardised mortality ratio
(SMR) was measured as 3.53 (95% CI 3.03 to
4.11) and adjusted metaregression did not
show significant changes in SMR over time.2
Nevertheless, some reports did suggest an
improved survival in recent years. In an
Italian study, the 10-year survival showed a
clear-cut increase (81%) compared with
older series (69%) from the same centre.3
However, the discrepancy may not only come
from improved therapeutic management, but
might be due to some changes in the natural
history, to an earlier referral of the patients
and, even more likely, to the better recogni-
tion of patients with milder disease.
Accordingly, in the recent Italian series,
there were more patients with the limited
cutaneous SSc (LcSSc) than in the older
study (87.5% vs 72%).3 In terms of organ
involvement and progression of the disease,
the outcomes in LcSSc and diffuse cutaneous
SSc (DcSSc) are different. The new classifica-
tion criteria will more easily identify patients
with LcSSc.4 Therefore, it will become core
to require the cutaneous subsetting for any
scientific work on SSc and, beyond skin, sub-
classification or clustering is awaited to
improve SSc patient risk stratification.
Regarding morbidity, accumulating evidence
has shown the huge impact of SSc on quality
of life (QOL). With the support of patients
associations and international medical soci-
eties, we have performed a large survey
(1902 patients with SSc from 60 countries).
The results confirmed the impaired QOL in
SSc as measured by the short-form 36
(SF-36) questionnaire; it was particularly
marked for physical health (mean±SD 43.4
±23.4; 100=best health), but mental health
was also impaired (mean±SD 52.3±23.1).5
Patients with DcSSc had poorer QOL scores
than patients with LcSSc, for the physical
(mean±SD 39.8±22.3 vs 46.6±23.7; p<0.0001)
and mental (mean±SD 50.3±23.2 vs 53.8
±23.0; p=0.003) components.5 The dimen-
sion of QOL and patient-reported outcomes
is moving in SSc, and it should provide
meaningful information on future drugs.
The majority of ongoing or upcoming
trials target skin fibrosis and the early DcSSc
subset. Indeed, no drug has been so far
labelled according to the properties to
reduce skin fibrosis or organ involvements.
Many trials failed in the past and one might
question whether the failure is mostly driven
by the wrong choice of the drug, the use of
imprecise outcome measures or imperfect
selection of the included patients. Regarding
the drug to be investigated, we will comment
later on the new trials, but it is obvious that
SSc is far more than a ‘simple’ inflammatory
or autoimmune disease. The relationships
between vasculopathy, immune disturbances
and fibroblast activation are complex and
may challenge the identification of the effi-
cacy of a single therapeutic agent. Regarding
outcome measures, although not perfect,
several lines of evidence have shown that
skin sclerosis measured by the modified
Rodnan skin score (mRSS) is a robust surro-
gate marker for SSc. The last point about the
targeted population has been addressed by
several recent studies.6 One of the methodo-
logical issues in past trials has been the
observation that the control arm experi-
enced a decrease in mRSS. Therefore, the
drug under investigation had to show further
acceleration of the decrease in skin fibrosis
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that was already ‘naturally’ ongoing. Despite the patho-
genesis of scleroderma starts to be better known, this
very SSc-specific natural regression of skin fibrosis after
few years of extracellular matrix accumulation still
remains poorly understood. One recent study has shed
new lights that may translate in future trials; it highlights
a regulatory role of the nuclear receptor NR4A1 in
transforming growth factor β (TGF-β) signalling and
fibrosis, providing the first proof of concept for targeting
NR4A1 in fibrotic diseases.7 If accelerating the spontan-
eous decrease is very challenging, one might question
how we could target patients earlier at the time when
matrix deposition starts or is active. This has been the
matter of European Scleroderma Trials and Research
group (EUSTAR) project that aimed at identifying the
parameters predicting skin progression in patients with
DcSSc. A total of >800 patients with mRSS≥7 at baseline
visit, valid data for mRSS at second visit, and available
follow-up of 12±2 months were studied. Worsening of
skin fibrosis defined as increase in mRSS>5 points and
≥25% from baseline to second visit was observed in
about 10% of the patients. The univariate and multivari-
ate analyses primarily suggested that joint synovitis, short
disease duration and lower mRSS at baseline were pre-
dictive of progressive skin disease.8 One important result
was by example that 12.3% of patients with a low mRSS
at baseline (≤22/51) were progressing compared with
only 2.9% with an mRSS>22/51 (p<0.001). Regarding
disease duration, the difference in the cumulative per-
centage between progressors and non-progressors
increased within 15 months and stayed stable, emphasis-
ing that progressors must be captured early in the
course of the disease.8 It must be pointed out that the
analyses were made for 12-month follow-up, which is
considered by many experts as the optimal trial duration
to detect meaningful changes in skin fibrosis. Additional
analyses (yet unpublished) have been performed using
this cohort. For example, although it could have been
intuitive to believe that recent disease activity could
predict further skin progression, we observed that the
‘patient-reported worsening of skin fibrosis’ within the
past month prior to baseline, the modified skin progres-
sion rate at baseline and progression of skin fibrosis in
the previous year were not associated with progression of
skin fibrosis. Indeed, previous activity appears to enrich
for patients that have already reached their peak skin
score. We also aimed to identify patients with ‘natural’
regression of skin fibrosis, as these patients might
benefit less from therapeutic interventions and might
not be the right candidates for clinical trials. Again,
baseline mRSS was an important parameter and patients
with high baseline mRSS were most likely to improve,
whereas presence of tendon friction rubs was inversely
correlated.9 Altogether, baseline mRSS appears as key to
predict progression/regression in patients with SSc at
least in the DcSSc and in the earlier years.
This observation is pivotal for clinical practice and clin-
ical study design. In fact in early DcSSc, it strongly
supports a therapeutic window of opportunity before
severe skin fibrosis has occurred. Indeed, most recently
performed clinical trials that failed to show any efficacy
used a minimum mRSS of 16–20 as an inclusion criterion
and recruited patients with an average baseline mRSS of
25/51.10 While this is unlikely to be the only explanation
for a negative study, high baseline mRSS and the resulting
ceiling effect and regression to the mean effect might be
an important factor contributing to the failure of clinical
trials in skin fibrosis. The above EUSTAR data were mainly
obtained from European patients and it must be high-
lighted that ethnic/geographical influences can affect
SSc. For example, while anti-RNA polymerase III (RNA
pol III) antibodies are rare in Europeans, its frequency
can reach 20–25% of patients in the USA.11–13 These
patients reach early their peak in skin fibrosis (reflected
by early high skin score), and then also decrease more
promptly than negative patients. Therefore, the time of
recruitment and time for end point will have to be estab-
lished in RNA pol III patients. Beyond inclusion criteria,
improving outcome measures is another way to improve
clinimetrics in SSc trials and the development of a com-
posite index (Combined Response Index for Systemic
Sclerosis, CRISS) is an important achievement.14 The
composite response index for trials of early DcSSc
includes core items that assess change in two prominent
manifestations of early DcSSc (skin and interstitial lung
disease), functional disability (Health Assessment
Questionnaire Disability Index, HAQ-DI) and patient and
physician global assessments. In addition, the score cap-
tures a clinically meaningful worsening of internal organ
involvement requiring treatment.14 It is included in the
majority of ongoing trials for further validation.
The current era for the treatment of SSc is probably
the most exciting of the last decades. Several explana-
tions support the major interest in SSc by investigators
and pharmaceutical companies. First, huge develop-
ments have been achieved in other autoimmune diseases
such as rheumatoid arthritis, but further improvements
in these areas are very challenging and require major
investments. Today, the SSc clinical spectrum is better
known and defined, but unmet needs still remain a crit-
ical issue in this rare disease. Refocusing immunother-
apies, already used by the rheumatologists in other
diseases, makes sense and is in line with the genetic data
that demonstrated the shared autoimmunity between
several different autoimmune diseases.15 Concomitantly,
drug agencies offer special pathways for the develop-
ment of drugs in the field of rare diseases that can
clearly accelerate approval of specific treatments. Finally,
fibrosis contributes to as much as 45% of deaths in the
industrialised countries.16 Furthermore, as pulmonary,
renal, hepatic and even dermal fibrosis share common
pathways, SSc is considered as a prototype entity for
fibrotic diseases. Therefore, progresses made in SSc are
expected to be translated into other fibrotic conditions.
It is striking to see that when querying the clinicaltrial.
gov website, about 300 studies are found for the term
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‘systemic sclerosis’ with >200 interventional studies. A
careful look at clinical trial details provides >50 phase
II/III trials with about 20 trials on active recruitment.
The major active studies are listed in table 1. The major-
ity of the ongoing studies target skin fibrosis, and inter-
leukin 6,17 interleukin 1 and CTLA418 are targeted
using compounds already on the market. The results of
faSScinate trial evaluating tocilizumab are very encour-
aging to finally get one positive trial on mRSS.17 The
results of this study showed not only an improvement in
skin fibrosis but there was also an encouraging signal on
changes in pulmonary functional tests to be both con-
firmed in the ongoing large phase III focuSSced trial. It
is also interesting to see that drugs with other mechan-
ism of action that showed very promising preclinical
data are developed for fibrosis. These drugs can be
regarded as potential antifibrotic ones with various
actions: riociguat is a stimulator of soluble guanylate
cyclase,19 whereas IVA337 is a panPPAR agonist.20 With
regard to the complex pathogenesis of SSc, one might
anticipate in the near future that combination therapies
will have to be investigated and accordingly first
investigating immunotherapies and antifibrotic drugs
separately makes sense. However, in an optimistic and
ambitious vision, the very efficient treatment might be
their combination. The above-cited trials all target
enriched population at various levels, but riociguat and
IVA337 studies include patients with early DcSSc with
lower baseline mRSS, in line with the recent EUSTAR
findings. Lung is another key target for SSc and the
recent approval of nintedanib in idiopathic lung fibrosis
together with good preclinical data has allowed the large
ongoing trial on SSc.21 Intense immunosuppression,
achieved with hematopoietic stem cell transplantation,
showed a significant decrease in patients reaching end
organ failure, but more data are needed to further clarify
the risk/benefit ratio and the criteria that may select
patient for such therapy.22 Gastrointestinal (GI) involve-
ment is not the most severe complication of the disease,
but it is very prevalent and disabling. Specific data on SSc
GI system will be important for the routine management
of the patients. Pulmonary arterial hypertension is prob-
ably less prevalent than it was few years ago, but it still
remains a very severe complication with poor outcomes.23
Table 1 Main ongoing phase II/III clinical trials on systemic sclerosis
Title Primary outcome Reference
Efficacy and Safety of riociguat in patients with systemic sclerosis Change in mRSS NCT02283762
Proof-of-concept trial of IVA337 in diffuse cutaneous systemic sclerosis
(FASST)
Change in mRSS NCT02503644
IVIG treatment in systemic sclerosis Change in mRSS NCT01785056
A study of the efficacy and safety of tocilizumab in participants with
Systemic Sclerosis (SSc) (focuSSced)
Change in mRSS NCT02453256
A Study of subcutaneous abatacept to treat diffuse cutaneous Systemic
Sclerosis (ASSET)
Incidence of adverse events/
change in mRSS
NCT02161406
IL1-TRAP, Rilonacept, in Systemic Sclerosis 4-gene skin biomarker NCT01538719
Cyclophosphamide systemic sclerosis-associated interstitial lung
disease
Forced vital capacity NCT01570764
Rituximab versus cyclophosphamide in connective tissue disease-ILD
(RECITAL)
Absolute change in FVC NCT01862926
A trial to compare nintedanib with placebo for patients with scleroderma
related lung fibrosis
Annual rate of decline in
FVC in mL
NCT02597933
Scleroderma treatment with autologous transplant (STAT) study Event-free survival NCT01413100
Autologous stem cell SSc immune suppression trial (DIScl2011) Time to treatment failure NCT01445821
Allogeneic hematopoietic cell transplantation after non-myeloablative
conditioning for patients with severe Systemic Sclerosis
Event-free survival NCT00622895
Clinical trial of probiotics in Systemic Sclerosis associated
gastrointestinal disease
Gastrointestinal change score NCT01804959
Gastroesophageal reflux treatment in scleroderma (GERD-SSc) Change in severity of heart burn
and regurgitation
NCT01878526
Rituximab for treatment of Systemic Sclerosis-Associated pulmonary
arterial hypertension (SSc-PAH)
Change in pulmonary vascular
resistance
NCT01086540
Early treatment of borderline pulmonary arterial hypertension associated
with Systemic Sclerosis (SSc-APAH) (EDITA)
Mean pulmonary arterial pressure
change from baseline
NCT02290613
Zibotentan better renal scleroderma outcome study (ZEBRA) Biomarker (sVCAM 1) NCT02047708
Safety, tolerability, efficacy, and pharmacokinetics of JBT-101 in




Subcutaneous injection of autologous adipose tissue-derived stromal
vascular fraction into the fingers of patients with systemic sclerosis
(scleradec2)
Cochin hand functional scale NCT02558543
CRISS, Combined Response Index for Systemic Sclerosis; mRSS, modified Rodnan skin score.
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The analysis of the literature shows that the scientific
work and clinical trials in SSc are numerous. SSc com-
plexity and severity have attracted several investigators
and pushed towards the building of very active networks
to share ideas and forces to improve the field.24 A better
understanding of the pathogenesis, the natural history
and the identification of parameters for selecting
enriched populations are already major achievements
and raise hope for patients with SSc. Our community
must further foster collaborations between scientists,
and with companies, to translate all the efforts that are
made into clinical care to improve the QOL and survival
of patients with SSc.
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